drugset / Trial / NCT01896440

Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

NCT01896440

Phase 4 Withdrawn University of Oklahoma
RandomizedCrossoverQuadruple-blindTreatment

Summary

We will study the effects of ondansetron on measurements of electrical activity in the heart to make sure doses we are using to prevent nausea and vomiting in children receiving chemotherapy are safe.

Timeline

Start
2013-10
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 0.15 mg/kg Intravenous
Comparator Ondansetron Other / unclassified 0.3 mg/kg Intravenous